Reimbursed Care Access in Romania

Currently classified as a strictly controlled substance under national drug‑scheduling laws, with no authorized medical use outside of approved clinical research. National schedules and annex tables under Law No. 143/2000 and subsequent updates list psilocin/psilocybin among controlled hallucinogens; possession, distribution or use outside research is criminalized. # #

Currently classified as a strictly controlled substance under national drug‑scheduling laws, with no authorized medical use outside of approved clinical research. MDMA (ecstasy) is listed among high‑risk/hallucinogenic substances in the annexed tables to Law No. 143/2000; there is no national reimbursement pathway for MDMA‑assisted therapy and recreational possession/trafficking is criminally penalized. #

Esketamine (Spravato®) is an approved medicinal product in Romania with defined healthcare guidance for professional use. The Romanian National Agency for Medicines and Medical Devices (Agenția Națională a Medicamentului și a Dispozitivelor Medicale — ANMDMR) maintains product pages, professional checklists and patient guides for SPRAVATO, indicating regulatory approval and a controlled, supervised distribution model in certified healthcare settings. Use is restricted to indicated clinical populations and administered under medical supervision in line with product guidance. #

Reimbursement and coverage: while SPRAVATO is a registered medicinal product, national public reimbursement (CNAS) coverage is limited in practice and generally depends on meeting strict clinical criteria (e.g., treatment‑resistant depression) and hospital/clinic contracting with payors. In Romania, high‑cost specialty psychiatric therapies frequently require case‑by‑case negotiations between hospital programs/clinics and payors or rely on private payment; no broad, automatic outpatient reimbursement program for esketamine equivalent to some larger EU countries has been published by ANMDMR. Clinicians and institutions therefore typically deliver Spravato within hospital or certified outpatient programs under direct billing/contract arrangements rather than as an automatic primary‑care reimbursed prescription. #

Ketamine is an authorised and widely used anaesthetic and analgesic in Romania (and across EU health systems) and is included in standard hospital formularies for procedural anaesthesia and acute pain management; it therefore has recognized medical status for these indications. Clinical literature and Romanian specialist summaries describe ketamine's routine anaesthetic and analgesic indications and note emerging off‑label use at sub‑anaesthetic doses for refractory pain and treatment‑resistant depression under specialist supervision. # #

Reimbursement and access specifics: approved indications (anaesthesia and acute analgesia) are delivered and reimbursed through standard hospital funding and procurement channels. Psychiatric use of ketamine for depression in Romania remains off‑label; such treatments, when provided, are typically privately funded or delivered within clinical trials or hospital programs and do not have an established, routine public reimbursement pathway. Off‑label psychiatric administration is expected to follow clinical governance standards, specialist oversight, and local institutional approval. # #

Currently classified as a strictly controlled substance under national drug‑scheduling laws, with no authorized medical use outside of approved clinical research. DMT and DMT‑containing preparations are covered by Romania's controlled‑substance schedules (annexes to Law No. 143/2000), meaning possession, distribution or use outside authorised research is unlawful. # #

Currently classified as a strictly controlled substance under national drug‑scheduling laws, with no authorized medical use outside of approved clinical research. 5‑MeO‑DMT is treated as a controlled tryptamine analogue in Romania and is not available clinically or via reimbursement outside research. #

Currently classified as a strictly controlled substance under national drug‑scheduling laws, with no authorized medical use outside of approved clinical research. Systematic reviews and regulatory summaries list ibogaine as illegal in multiple European countries including Romania, and it has no authorized medical reimbursement pathway there; its use persists only in clandestine or overseas clinics. #

Currently classified as a strictly controlled substance under national drug‑scheduling laws, with no authorized medical use outside of approved clinical research. Because the active principle (DMT) is a scheduled substance, ayahuasca preparations containing DMT are not authorised for medical use in Romania and the drink occupies a prohibited/status‑controlled legal position; any ceremonial or commercial provision would be subject to criminal law unless part of an approved clinical trial. # #

Currently classified as a strictly controlled substance under national drug‑scheduling laws, with no authorized medical use outside of approved clinical research. Mescaline and certain cactus sources (except limited religious/heritage carve‑outs in some jurisdictions) are included in Romania's controlled substance tables; mescaline possession, manufacture or distribution is criminalized except within authorised research protocols. # #

Currently classified as a strictly controlled substance under national drug‑scheduling laws, with no authorized medical use outside of approved clinical research. Romania's analogue and scheduling provisions (Legea nr. 143/2000 and subsequent amendments such as emergency/additional scheduling acts) have been used to add NPS and 2C‑type phenethylamines to controlled lists; production, possession or distribution outside research is prohibited and punishable. Recent updates to schedules (e.g., 2025 amendments) demonstrate active expansion of controlled lists to include new psychoactive substances. # #